VIDEO: Tremfya safe, efficacious for moderately to severely active Crohn’s
Click Here to Manage Email Alerts
SAN DIEGO — In this video exclusive, Remo Panaccione, MD, of the University of Calgary, discussed a study assessing the safety and efficacy of Tremfya in patients with moderately to severely active Crohn’s disease.
During the GALAXI1, phase 2, double-blind, placebo-controlled, multicenter study, patients were randomly assigned to Tremfya (guselkumab, Janssen) dosed 200 mg, 600 mg or 1,200 mg intravenously, Stelara (ustekinumab, Janssen) dosed approximately 6 mg/kg intravenously to 90 mg subcutaneously, or intravenous placebo during the induction phase.
The results, presented at Digestive Disease Week 2022, included 248 patients were randomly assigned to guselkumab or ustekinumab. After patients completed 12 weeks of the induction therapy, patients were transitioned to long-term treatment arms, Panaccione noted.
According to Panaccione, guselkumab was safe and effective for Crohn’s disease. At week 48, guselkumab induction and maintenance achieved high rates of clinical and endoscopic efficacy.
“In the end, this is exciting news from a phase 2, dose ranging study,” Panaccione said.
“We’re eagerly awaiting the completion and the results of the phase 3 trial because this may become an exciting new treatment option for our patients with moderately to severely active Crohn’s disease.”
Collapse
Healio Interviews
Panaccione R, et al. Abstract 888. Presented at: Digestive Disease Week; May 21-24, 2022; San Diego (hybrid meeting).
Read more about
Click Here to Manage Email Alerts